CLINICAL_TRIALS trial_result · 2010-10-01

Clinical Trial Update: Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC) [Phase 3]

Phase III trial evaluating sorafenib in renal cell carcinoma has been completed, with results posted in October 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED | Results posted: 2010-10-01